Neurogene Inc. (NASDAQ: NGNE) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $54.00 price target on the stock.
Neurogene to Participate in Upcoming Conferences
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program [Yahoo! Finance]